Epitope Landscape in Breast and Colorectal Cancer
Abstract
The finding that individual cancers contain many mutant genes not present in normal tissues has prompted considerable interest in the cancer epitope landscape. To further understand such effects, we applied in silico–based epitope prediction algorithms and high throughput post hoc analysis to identify candidate tumor antigens. Analysis of 1,152 peptides containing missense mutations previously identified in breast and colorectal cancer revealed that individual cancers accumulate on average ∼10 and ∼7 novel and unique HLA-A*0201 epitopes, respectively, including genes implicated in the neoplastic process. These data suggest that, with appropriate manipulation of the immune system, tumor cell destruction in situ may provide a polyvalent tumor vaccine without a requirement for knowledge of the targeted antigens. [Cancer Res 2008;68(3):889–92]
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
During radiotherapy or chemotherapy, immune responses may be biased toward tumor antigens rather than normal self-antigens.
“Consequently, during radiotherapy or chemotherapy in which the tumor cells are induced to die, immune responses may be biased towards a response against the tumor antigens rather than normal self-antigens, to which the immune system has been tolerized 7,27,28.”
From Immunogenic and tolerogenic cell death (2009) · cites this paper as [27]
HMGB1 can be released during secondary necrosis following apoptosis, not only from the nucleus during primary necrosis.
“Although it was initially thought that HMGB1 is released only from the nucleus during primary necrosis, recent data indicate that HMGB1 can be released during secondary necrosis following apoptosis 27,48–50.”
From Immunogenic and tolerogenic cell death (2009) · cites this paper as [27]
Depletion of HMGB1 from tumor cells undergoing immunogenic apoptosis abolishes their ability to induce T-cell priming or protect mice against tumor growth following vaccination, indicating HMGB1 is required for immunogenicity of cell death.
“Depletion of HMGB1 from tumor cells undergoing immunogenic apoptosis (induced by anthracyclins, oxaliplatin or ionizing irradiation) abolishes their ability to induce T-cell priming or to protect mice against tumor growth following vaccination27, indicating that this DAMP is required for the immunogenicity of cell death.”
From Immunogenic and tolerogenic cell death (2009) · cites this paper as [27]
Cites
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161 · see citing works
Self-citationThe Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,087 · see citing works
SYFPEITHI: database for MHC ligands and peptide motifs
Rammensee, H., Bachmann, J., Emmerich, N., Bachor, O. A., & Stevanović, S. (1999) · Immunogenetics · doi:10.1007/s002510050595 · Cited by 2,316 · see citing works
Seung, H., Opper, M., & Sompolinsky, H. (1992) · Annual Conference Computational Learning Theory · doi:10.1145/130385.130417 · Cited by 2,193 · see citing works
Parker, K. C., Bednarek, M. A., & Coligan, J. E. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.1.163 · Cited by 1,378 · see citing works
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
Chen, Y., Scanlan, M. J., Şahin, U., Türeci, Ö., Gure, A. O., Tsang, S., Williamson, B., Stockert, E., Pfreundschuh, M. G., & Old, L. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.1914 · Cited by 1,247 · see citing works
Immunity to Methylcholanthrene-Induced Sarcomas
Prehn, R. T., & Main, J. M. (1957) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/18.6.769 · Cited by 1,230 · see citing works
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann, E., Plaen, E. D., Hankeln, T., Büschenfelde, K. M. Z., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,153 · see citing works
Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, T., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3515 · Cited by 1,093 · see citing works
Reliable prediction of T‐cell epitopes using neural networks with novel sequence representations
Nielsen, M., Lundegaard, C., Worning, P., Lauemøller, S. L., Lamberth, K., Buus, S., Brunak, S., & Lund, O. (2003) · Protein Science · doi:10.1110/ps.0239403 · Cited by 1,075 · see citing works
Coulie, P. G., Brichard, V. G., Pel, A. V., Wölfel, T., Schneider, J., Traversari, C., Mattei, S., Plaen, E. D., Lurquin, C., Szikora, J., et al. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.180.1.35 · Cited by 903 · see citing works
Klein, G., Sjögren, H. O., Klein, E., & Hellström, K. E. (1960) · PubMed · Cited by 742 · see citing works
Traversari, C., van der Bruggen, P., Luescher, I. F., et al. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.176.5.1453 · Cited by 693 · see citing works
Checkpoint Blockade in Cancer Immunotherapy
Korman, A. J., Peggs, K. S., & Allison, J. P. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90008-x · Cited by 577 · see citing works
Self-citationAntigenicity of Murine Skin Tumors Induced by Ultraviolet Light2
Kripke, M. L. (1974) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/53.5.1333 · Cited by 481 · see citing works
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens
Lennerz, V., Fatho, M., Gentilini, C., Frye, R. A., Lifke, A., Ferel, D., Wölfel, C., Huber, C., & Wölfel, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500090102 · Cited by 458 · see citing works
Cao, K., Hollenbach, J. A., Shi, X., Shi, W., Chopek, M. W., & Fernández-Viña, M. (2001) · Human Immunology · doi:10.1016/s0198-8859(01)00298-1 · Cited by 458 · see citing works
The Makings of a Tumor Rejection Antigen
Gilboa, E. (1999) · Immunity · doi:10.1016/s1074-7613(00)80101-6 · Cited by 382 · see citing works
Prediction of MHC class I binding peptides using profile motifs
Reche, P. A., Glutting, J.-P., & Reinherz, E. L. (2002) · Human Immunology · doi:10.1016/s0198-8859(02)00432-9 · Cited by 376 · see citing works
Buus, S., Lauemøller, S. L., Worning, P., et al. (2003) · Tissue Antigens · doi:10.1034/j.1399-0039.2003.00112.x · Cited by 342 · see citing works
A CASP-8 Mutation Recognized by Cytolytic T Lymphocytes on a Human Head and Neck Carcinoma
Mandruzzato, S., Brasseur, F., Andry, G., Boon, T., & van der Bruggen, P. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.5.785 · Cited by 321 · see citing works
Elkington, R., Walker, S., Crough, T., Menzies, M., Tellam, J., Bharadwaj, M., & Khanna, R. (2003) · Journal of Virology · doi:10.1128/jvi.77.9.5226-5240.2003 · Cited by 308 · see citing works
PAProC: a prediction algorithm for proteasomal cleavages available on the WWW
Nussbaum, A. K., Kuttler, C., Hadeler, K.-P., et al. (2001) · Immunogenetics · doi:10.1007/s002510100300 · Cited by 192 · see citing works
An algorithm for the prediction of proteasomal cleavages
Kuttler, C., Nussbaum, A. K., Dick, T. P., et al. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3683 · Cited by 154 · see citing works
MAPPP: MHC class I antigenic peptide processing prediction.
Hakenberg, J., Nussbaum, A. K., Schild, H., et al. (2003) · PubMed · Cited by 111 · see citing works
Multiple tumour-specific antigens expressed on a single tumour cell
Wortzel, R. D., Philipps, C., & Schreiber, H. W. (1983) · Nature · doi:10.1038/304165a0 · Cited by 108 · see citing works
An Artificial Neural Network Approach
Kim, S. H., Park, K. S., & Kim, J. K. (1993) · Proceedings of · Cited by 37 · see citing works
Gómez‐Núñez, M., Pinilla-Ibarz, J. A., Dao, T., et al. (2006) · Leukemia Research · doi:10.1016/j.leukres.2006.02.010 · Cited by 33 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · see citing works
Self-citationMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · see citing works
Self-citationNeoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783 · see citing works
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071 · see citing works
Self-citationGenetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · see citing works
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893 · see citing works
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301 · see citing works
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345 · see citing works
Self-citationLlosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487 · see citing works
Self-citationImmunogenic and tolerogenic cell death
Green, D. R., Ferguson, T., Zitvogel, L., & Kroemer, G. (2009) · Nature Reviews Immunology · doi:10.1038/nri2545 · Cited by 1,176 · see citing works
Targeting neoantigens to augment antitumour immunity
Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.154 · Cited by 997 · see citing works
van Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L. J. A., Behjati, S., Hilkmann, H., el Atmioui, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7521 · Cited by 798 · see citing works
Kim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410626111 · Cited by 676 · see citing works
Self-citationSingle-cell analysis tools for drug discovery and development
Heath, J. R., Ribas, A., & Mischel, P. S. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.16 · Cited by 473 · see citing works
IL-10 Elicits IFNγ-Dependent Tumor Immune Surveillance
Mumm, J. B., Emmerich, J., Zhang, X., Chan, I., Wu, L., Mauze, S., Blaisdell, S., Basham, B., Dai, J., Grein, J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.003 · Cited by 418 · see citing works
Sharma, P., Pachynski, R. K., Narayan, V., Fléchon, A., Gravis, G., Galsky, M. D., Mahammedi, H., Patnaik, A., Subudhi, S. K., Ciprotti, M., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.007 · Cited by 406 · see citing works
Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy
Vesely, M. D., & Schreiber, R. D. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12105 · Cited by 367 · see citing works
Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy
Lee, N., Zakka, L. R., Mihm, M. C., & Schatton, T. (2016) · Pathology · doi:10.1016/j.pathol.2015.12.006 · Cited by 250 · see citing works
Acquired and intrinsic resistance in cancer immunotherapy
Kelderman, S., Schumacher, T. N. M., & Haanen, J. B. A. G. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.011 · Cited by 197 · see citing works
Subudhi, S. K., Vence, L., Zhao, H., Blando, J., Yadav, S. S., Xiong, Q., Reuben, A., Aparicio, A., Corn, P. G., Chapin, B. F., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz3577 · Cited by 158 · see citing works
Vaccine therapy for pancreatic cancer
Salman, B., Zhou, D., Jaffee, E. M., Edil, B. H., & Zheng, L. (2013) · OncoImmunology · doi:10.4161/onci.26662 · Cited by 64 · see citing works
Mumm, J. B., & Oft, M. (2013) · BioEssays · doi:10.1002/bies.201300004 · Cited by 53 · see citing works
- Authors
- Segal, N. H., Parsons, D. W., Peggs, K. S., Velculescu, V., Kinzler, K. W., Vogelstein, B., & Allison, J. P.
- Affiliations
- 1Department of Medicine,
- Johns Hopkins University (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Venue
- Cancer Research
- Published
- 2008-02-01
- Volume
- 68
- Issue
- 3
- Pages
- 889-892
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2087751238
- Cited by
- 416
- References
- 28
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 24 · 2023: 14 · 2022: 17 · 2021: 28 · 2020: 31 · 2019: 24 · 2018: 32 · 2017: 29 · 2016: 35 · 2015: 45 · 2014: 30 · 2013: 34 · 2012: 19
- FWCI
- 5.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- tumor antigens, breast cancer, colorectal cancer, missense mutations, epitope prediction, tumor immunology
- MeSH terms
- Algorithms, Epitopes, Breast Neoplasms, Humans, Colorectal Neoplasms, HLA-A Antigens, HLA-A2 Antigen, Mutation, Missense
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
